Hepatitis Monthly

Published by: Kowsar

Interferon Alpha-2b Therapy in Chronic Hepatitis Delta

Maryam Keshvari 1 , 2 , Seyed Moayed Alavian 2 , * , Heidar Sharafi 2 , Gharib Karimi 1 and Mohammad Gholami Fesharaki 3
Authors Information
1 Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine,Tehran, IR Iran
2 Middle East Liver Disease (MELD) Center, Tehran, IR Iran
3 Department of Biostatistics, School of Medical Sciences, Tarbiat Modares University, Tehran, IR Iran
Article information
  • Hepatitis Monthly: March 01, 2014, 14 (3); e15729
  • Published Online: March 1, 2014
  • Article Type: Research Article
  • Received: October 28, 2013
  • Revised: December 4, 2013
  • Accepted: January 22, 2014
  • DOI: 10.5812/hepatmon.15729

To Cite: Keshvari M, Alavian S M, Sharafi H, Karimi G, Gholami Fesharaki M. Interferon Alpha-2b Therapy in Chronic Hepatitis Delta, Hepat Mon. 2014 ; 14(3):e15729. doi: 10.5812/hepatmon.15729.

Copyright © 2014, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Rizzetto M, Canese MG, Arico S, Crivelli O, Trepo C, Bonino F, et al. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut. 1977; 18(12): 997-1003[PubMed]
  • 2. Wedemeyer H, Yurdaydin C, Dalekos GN, Erhardt A, Cakaloglu Y, Degertekin H, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med. 2011; 364(4): 322-31[DOI][PubMed]
  • 3. Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet. 2011; 378(9785): 73-85[DOI][PubMed]
  • 4. Husa P, Linhartova A, Nemecek V, Husova L. Hepatitis D. Acta Virol. 2005; 49(4): 219-25[PubMed]
  • 5. Alavian S, Alavian S. Hepatitis D Virus Infection; Iran, Middle East and Central Asia. Hepat Mon. 2005; : 137-43
  • 6. Yurdaydin C, Bozkaya H, Karaaslan H, Onder FO, Erkan OE, Yalcin K, et al. A pilot study of 2 years of interferon treatment in patients with chronic delta hepatitis. J Viral Hepat. 2007; 14(11): 812-6[DOI][PubMed]
  • 7. Farci P, Chessa L, Balestrieri C, Serra G, Lai ME. Treatment of chronic hepatitis D. J Viral Hepat. 2007; 14 Suppl 1: 58-63[DOI][PubMed]
  • 8. Madejon A, Cotonat T, Bartolome J, Castillo I, Carreno V. Treatment of chronic hepatitis D virus infection with low and high doses of interferon-alpha 2a: utility of polymerase chain reaction in monitoring antiviral response. Hepatology. 1994; 19(6): 1331-6[PubMed]
  • 9. Yurdaydin C, Idilman R, Bozkaya H, Bozdayi AM. Natural history and treatment of chronic delta hepatitis. J Viral Hepat. 2010; 17(11): 749-56[DOI][PubMed]
  • 10. Smedile A, Niro MG, Rizzetto M. Detection of serum HDV RNA by RT-PCR. Methods Mol Med. 2004; 95: 85-93[DOI][PubMed]
  • 11. Gheorghe L, Iacob S, Simionov I, Vadan R, Constantinescu I, Caruntu F, et al. Weight-based dosing regimen of peg-interferon alpha-2b for chronic hepatitis delta: a multicenter Romanian trial. J Gastrointestin Liver Dis. 2011; 20(4): 377-82[PubMed]
  • 12. Ho E, Deltenre P, Nkuize M, Delwaide J, Colle I, Michielsen P, et al. Coinfection of hepatitis B and hepatitis delta virus in Belgium: a multicenter BASL study. Prospective epidemiology and comparison with HBV mono-infection. J Med Virol. 2013; 85(9): 1513-7[DOI][PubMed]
  • 13. Kaymakoglu S, Karaca C, Demir K, Poturoglu S, Danalioglu A, Badur S, et al. Alpha interferon and ribavirin combination therapy of chronic hepatitis D. Antimicrob Agents Chemother. 2005; 49(3): 1135-8[DOI][PubMed]
  • 14. Niro GA, Smedile A, Ippolito AM, Ciancio A, Fontana R, Olivero A, et al. Outcome of chronic delta hepatitis in Italy: a long-term cohort study. J Hepatol. 2010; 53(5): 834-40[DOI][PubMed]
  • 15. Farci P, Mandas A, Coiana A, Lai ME, Desmet V, Van Eyken P, et al. Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med. 1994; 330(2): 88-94[DOI][PubMed]
  • 16. Gaudin JL, Faure P, Godinot H, Gerard F, Trepo C. The French experience of treatment of chronic type D hepatitis with a 12-month course of interferon alpha-2B. Results of a randomized controlled trial. Liver. 1995; 15(1): 45-52[PubMed]
  • 17. Lau JY, King R, Tibbs CJ, Catterall AP, Smith HM, Portmann BC, et al. Loss of HBsAg with interferon-alpha therapy in chronic hepatitis D virus infection. J Med Virol. 1993; 39(4): 292-6[PubMed]
  • 18. Battegay M, Simpson LH, Hoofnagle JH, Sallie R, Di Bisceglie AM. Elimination of hepatitis delta virus infection after loss of hepatitis B surface antigen in patients with chronic delta hepatitis. J Med Virol. 1994; 44(4): 389-92[PubMed]
  • 19. Rosina F, Pintus C, Meschievitz C, Rizzetto M. A randomized controlled trial of a 12-month course of recombinant human interferon-alpha in chronic delta (type D) hepatitis: a multicenter Italian study. Hepatology. 1991; 13(6): 1052-6[PubMed]
  • 20. Gunsar F, Akarca US, Ersoz G, Kobak AC, Karasu Z, Yuce G, et al. Two-year interferon therapy with or without ribavirin in chronic delta hepatitis. Antivir Ther. 2005; 10(6): 721-6[PubMed]
  • 21. Yurdaydin C, Bozkaya H, Onder FO, Senturk H, Karaaslan H, Akdogan M, et al. Treatment of chronic delta hepatitis with lamivudine vs lamivudine + interferon vs interferon. J Viral Hepat. 2008; 15(4): 314-21[DOI][PubMed]
  • 22. Gulsun S, Tekin R, Bozkurt F. Treatment of chronic delta hepatitis: a nine-year retrospective analysis. Hepat Mon. 2011; 11(9): 731-5[DOI][PubMed]
  • 23. Farci P, Roskams T, Chessa L, Peddis G, Mazzoleni AP, Scioscia R, et al. Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology. 2004; 126(7): 1740-9[PubMed]
  • 24. Niro GA, Ciancio A, Gaeta GB, Smedile A, Marrone A, Olivero A, et al. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology. 2006; 44(3): 713-20[DOI][PubMed]
  • 25. Abbas Z, Khan MA, Salih M, Jafri W. Interferon alpha for chronic hepatitis D. Cochrane Database Syst Rev. 2011; (12)[DOI][PubMed]
  • 26. Brichler S, Setshedi M, Renou C. Resolution of chronic hepatitis delta infection after five years of peginterferon-adefovir: lessons from a case report. Clin Res Hepatol Gastroenterol. 2013; 37(3)-4[DOI][PubMed]
  • 27. Lau DT, Kleiner DE, Park Y, Di Bisceglie AM, Hoofnagle JH. Resolution of chronic delta hepatitis after 12 years of interferon alfa therapy. Gastroenterology. 1999; 117(5): 1229-33[PubMed]
  • 28. Alavian SM, Tabatabaei SV, Behnava B, Rizzetto M. Standard and pegylated interferon therapy of HDV infection: A systematic review and meta- analysis. J Res Med Sci. 2012; 17(10): 967-74[PubMed]
  • 29. Karaca C, Soyer OM, Baran B, Ormeci AC, Gokturk S, Aydin E, et al. Efficacy of pegylated interferon-alpha treatment for 24 months in chronic delta hepatitis and predictors of response. Antivir Ther. 2013; 18(4): 561-6[DOI][PubMed]
  • 30. Lamers MH, Kirgiz OO, Heidrich B, Wedemeyer H, Drenth JP. Interferon-alpha for patients with chronic hepatitis delta: a systematic review of randomized clinical trials. Antivir Ther. 2012; 17(6): 1029-37[DOI][PubMed]
  • 31. Mansour W, Ducancelle A, Le Gal F, Le Guillou-Guillemette H, Abgueguen P, Pivert A, et al. Resolution of chronic hepatitis Delta after 1 year of combined therapy with pegylated interferon, tenofovir and emtricitabine. J Clin Virol. 2010; 47(1): 97-9[DOI][PubMed]
  • 32. Dastgerdi ES, Herbers U, Tacke F. Molecular and clinical aspects of hepatitis D virus infections. World J Virol. 2012; 1(3): 71-8[DOI][PubMed]
  • 33. Hadziyannis SJ. Use of alpha-interferon in the treatment of chronic delta hepatitis. J Hepatol. 1991; 13 Suppl 1-6[PubMed]
  • 34. Gish RG, Yi DH, Kane S, Clark M, Mangahas M, Baqai S, et al. Coinfection with hepatitis B and D: epidemiology, prevalence and disease in patients in Northern California. J Gastroenterol Hepatol. 2013; 28(9): 1521-5[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments